Synopsis

Study title
Effects of bisoprolol and atenolol on resting heart rate, Secondary objective 1. To compare the effect in other SNS indication of bisoprolol and atenolol in EH patients with RHR>70bpm 2. To compare the efficiency of bisoprolol and atenolol to attaining RHR<65bpm] 3. To compare the efficiency of bisoprolol and atenolol on peripheral blood pressure 4. To compare the safety and compliance of bisoprolol and atenolol treatment after RHR<65bpm
Study design and plan
A phase IV single-centre randomize controlled study. The patient will receive bisoprolol 5mg Qd.(or atenolol 25mg Bid) for 2 weeks. If his/her heart rate<65bpm, this initial dose will be prolonged for another 2 weeks before the observation is over.
If the heart rate>65bpm, the patient will receive bisoprolol 7.5mg Qd.( or atenolol 37.5mg Bid) for 2 weeks. Then if his/her heart rate<65bpm, this increased dose will be prolonged for another 2 weeks before the observation is over.
If the heart rate>65bpm, the patient will receive bisoprolol 10mg Qd.( or atenolol 50mg Bid) for 2 weeks. Then if his/her heart rate<65bpm, this increased dose will be prolonged for another 2 weeks before the observation is over. If the heart rate>65bpm, the observation is over directly.
Planned number of subjects 110patients
Diagnosis and main inclusion and exclusion criteria
Main Inclusion Criteria including: 
Background
The sympathetic nervous system (SNS) plays a role in the pathophysiology of chronic arterial hypertension by modifying cardiac output and peripheral vascular resistance [1, 2] . It is known that sympathetic nerve activity (SNA) can cause changes in blood pressure (BP) through the activation of baroreceptors [3, 4] . Although introduced into scientific practice, methods of SNA evaluation are not commonly used in a clinical setting. Analysis of baroreflex sensitivity (BRS) and heart rate variability (HRV) have been recommended as the diagnostic tools for evaluating SNA and can be found in clinical guidelines as basic assessment methods [5] [6] [7] .
Data suggest that low BRS and/or HRV are risk factors for cardiovascular morbidity and mortality [8] [9] [10] .
Increasing clinical evidence suggests that central aortic pressure (CAP), but not brachial BP, predicts cardiovascular events, because the left ventricle (LV) pumps directly against the afterload in the central arteries. Moreover, aortic systolic BP, pulse pressure (PP), and augmentation index (AIx) have been shown to be strong independent cardiovascular risk predictors in hypertensive populations [11] [12] [13] [14] [15] .
β-blockers (BBs) are believed to improve SNS function; however, clinical studies on the effects of BBs on HRV and/or BRS in hypertensive patients have shown mixed results [16, 17] . Moreover, it is noteworthy that in a series of studies [14, [18] [19] [20] [21] [22] . atenolol-based therapy was significantly less effective in lowering aortic systolic and pulse pressure than other hypertensive classes，which may be attributed to a different mechanism of atenolol, thus explaining the different clinical outcomes. Since β-blocking drugs might have heterogeneous effects on the arterial system and BRS depending on their pharmacologic
properties, further comparisons of the effects of BBs on the arterial system and BRS may be helpful [23] . Bisoprolol with its high β1-selectivity, long duration of action, and favorable 7 pharmacokinetic properties was shown to be an effective and safe antihypertensive agent [24, 25] . Supposedly, these properties of bisoprolol should be an advantage in clinical practice.
Therefore, the present study was designed to compare the effects of a highly selective β1blocker (bisoprolol) and a classical β-blocker (atenolol) on SNA and CAP in hypertensive patients with controlled heart rate. 
Study Objectives
Study Design
It is a single-centers, randomized study in China, and planed to enroll 110 essential hypertension patients from 1 sites, who will be assigned to two groups randomly. All the inclusive patients will be consistent with the diagnosis of essential hypertension, and have a resting heart rate(RHR) ≥70 beats per minutes(bpm).
The inclusive patients will be assigned to two groups as follow (ratio 1:1)
Arm A: bisoprolol, 5-10mg/day for a targeting heart rate of less than 65 bpm(96) Arm B: atenolol, 50-100mg/day for a targeting heart rate of less than 65 bpm (96)
The patient will receive bisoprolol 5mg Qd.(or atenolol 25mg Bid) for 2 weeks. If his/her heart rate<65bpm, this initial dose will be prolonged for another 2 weeks before the observation is over.
Study flow
Dosage adjustment
5.2 Trial design
Inclusion of Special Populations
This study will not include special populations such as children, pregnant women and subjects with genetic diseases.
Selection of Trial Population
Subjects enroll
All patients who meet the inclusion criteria but not the exclusion criteria can be enrolled into this study. 
Inclusion Criteria：
Randomization：
This study is a parallel, randomized, controlled study, Patient will be randomized by the predesigned randomization schedule using randomization envelop.
Criteria for Subject Withdrawal
Subjects are free to discontinue the trial at any time without giving their reasons.
A subject must be withdrawn in the event of any of the following:
1. Withdrawal of the subject's consent.
Occurrence of an exclusion criterion which is clinically relevant and affects
the subject's safety, if discontinuation is considered necessary by the Investigator.
3. Intolerance to Concor ® treatment.
4.
Occurrence of unexpected adverse events that are unacceptable in nature, severity and/or duration, or the frequency of known unacceptable adverse events is higher than expected.
Premature Discontinuation of the Trial
The trial may be stopped by the Investigator in the event of any of the following:
1. Medical or ethical reasons that hinder the continuation of the study.
Poor enrollment of subjects
3. Occurrence of unexpected adverse events that are unacceptable in nature, severity and/or duration, or the frequency of known unacceptable adverse events is higher than expected.
The whole trial may be temporarily suspended or permanently terminated. If premature discontinuation of the trial is decided, the ethics committee will be informed in accordance with applicable regulations.
Study Medicine
Medication
Bisoprolol should be taken in morning orally.
Atenolol should be taken in morning orally.
Dosage
Intial period(2 weeks)： Bisoprolol5mg qd or Atenolol50mg qd Extended treatment period(2 weeks): When patient's heart rate is lower than 65 bpm, keep the dosage for 2 more week.
Concomitant Medications and Therapies
During the trial, any concomitant drugs, such as anti-diabetic drugs, lipid lowering drugs, anticoagulants and heart failure treatments like diuretics and ACEI, may be continued provided that these drugs do not affect heart rate. All medications used 3 months before enrollment and during the entire trial should be recorded. The dosage of these drugs may be adjusted as long as there is no effect on the heart rate.
Non-permitted Medicines
CCB, ACEI, ARB, diuretics and β-blockers other than Concor ® are not permitted during the trial. Any overdose must be recorded in the CRF and reported to the Sponsor and relevant authorities.
Specification, Packaging and special precautions
Trial procedures and assessments
Trial schedule and assessment contents
The trial procedure and assessment contents are as follows:
1. Visit 1 -Week -1 (1 +3 day): this visit entails the following:
Before any procedures that are related to the trial is undertaken, informed consent of the patient should be obtained. Thereafter, basic information of the patient will be obtained and patients are screened for eligibility based on the inclusion and exclusion criteria.
①. Record birth date, gender, height, weight, waist circumstance, current medical condition and past medical history, including concomitant therapies.
④. Record AE and concomitant therapies.
Demographic and Other Baseline Characteristics
Demographic Statistics
Major demographic information is as follows:
1. Name initials 2. Birth date 3. Gender 4. Race
Informed Consent
Participants must sign a written informed consent.
Medical history
The following information will be collected for the medical history of the subjects:
1. To confirm whether the subjects meet the inclusion or exclusion criteria 2. Past and current medical history, smoker should be recorded smoking history.
3. Past therapies and current concomitant drugs.
Vital signs and physical examination
Vital signs and physical examination should at least include the following items:
1. General status:
 Heart rate (resting heart rate) measurement: sit rest for 5 minutes, no smoking, no excitatory food and beverage such as tea and coffee for 30 minutes, measurements are taken at sitting position for a continuous record of 3 minutes. Heartbeats in each minute are calculated and averaged to obtain the resting heart rate.
 Blood pressure measurement: sit rest for 5 minutes, no smoking, no excitatory food and beverage such as tea and coffee for 30 minutes, measurements are taken at sitting position, with the elbow at the same level with the heart. Diastolic blood pressure is recorded at the fifth Korotkoff sound, repeated after 2 minutes and averaged. If the difference in diastolic blood pressure readings is > 5mmHg, measurement is repeated again after 2 minutes, and the 3 readings are averaged.
2. Physical examination of the respiratory system 
24-hour ABPM
Blood pressure variability (BPV) was also calculated in ABPM
24-hour Holter
For dectect cardiac arrhythmia.
Assessment of Efficacy
Assessment of efficacy mainly includes the following items: 
Adverse Event
An adverse event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Investigators must assess the severity/intensity of adverse events according to the Qualitative Toxicity Scale as follows:
Mild:
The subject is aware of the event or symptom, but the event or symptom is easily tolerated.
Moderate:
The subject experiences sufficient discomfort to interfere with or reduce his or her usual level of activity.
Severe:
Significant impairment of functioning: the subject is unable to carry out usual activities.
Investigators must also systematically assess the causal relationship of AEs to Concor ® using the following definitions. Decisive factors for the assessment of causal relationship of an AE to the treatments include, but may not be limited to, temporal relationship between the AE and the treatments; known side effects of treatments; concomitant medication, course of the underlying disease or impact of other treatment.
Serious Adverse Event
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:
 Results in death.
 Is life-threatening. Relevant serious adverse events that need to be intensively monitored in this trial:
1. Ⅲ Degree atrioventricular block; 20 2. Severe asthma attack;
3. Cardiac arrest 4. Acute pulmonary edema;
5. Worsening heart failure;
6. Shock.
Events that Do Not Meet the Definition of an SAE
Elective hospitalizations to simplify study treatment or study procedures are not considered an SAE. However, all events leading to unplanned hospitalizations or unplanned prolongation of an elective hospitalization must be documented and reported as SAEs.
Recording Adverse Events
All adverse eventsoccurring during the study, whether serious or not, must be recorded in the Case Report Form (CRF), including its description, severity, duration (onset and resolution dates), causal relationship (i.e., whether the adverse event is related to the study treatment), any other potential causal factors, actions taken with the study drug (dose reduction, withdrawal…), required treatment, and outcome. In addition, for all serious adverse events, seriousness criteria must be documented and a specific safety report form must be completed.
Expedited Reporting of Serious Adverse Events
As soon as the Investigator detects a serious adverse event, as defined above, associated with the study medication, he/she will report it within 24 hours (by e-mail, phone, or fax) to princepal investigator Gao Pingjin.
The Investigator must promptly respond to any request for follow-up information or questions from the Sponsor. Serious adverse events occurring during the study must be monitored and followed up by the Investigator until stabilization or until the outcome is known, unless the subject is lost to follow-up. The Investigator will ensure any necessary additional therapeutic measures and follow-up procedures.
Reporting procedures and timelines for any new information on a previously reported serious adverse event (follow-up) are the same as for the original report.
Further to reporting serious adverse events to the Sponsor, the Investigator will comply with any applicable local pharmacovigilance requirements to report adverse reactions/events to national pharmacovigilance systems.
Other laboratory tests
During the study period, laboratory tests other than these specified in the protocol will be decided based on the needs of clinical conditions.
Statistics
Sample Size
This study will recruit 110 patients with RHR≥ 70bpm and mild or moderate blood pressure.
Randomization
Patient will be randomized in a 1:1ratio.
All subjects will be treated according to the dose approved for their condition, and the subsequent treatment will be carried out according to the standard care and medical practice of the study site. Therefore, no randomization is required for this study.
Endpoints
Primary Endpoint(s)
The primary endpoint is BRS and central blood pressure at Last visit.
Secondary Endpoint(s)
The secondary endpoints in this study include 
PP and ITT Analysis
The main analysis set will be defined as all subjects who receive at least one dose of any investigational medicinal product, i.e., the Intention-to-Treat (ITT) population. This population will be used for all efficacy evaluations. A secondary analysis set, the Per Protocol (PP) set, will also be defined, which will exclude all subjects found to have a major protocol deviation*.
*Deviation from the protocol will be determined by medical check.
Subgroup Analysis
Subgroup analysis will be conducted within the subgroups defined according to drug dosage.
Safety Analysis
The set of subjects included in the safety analysis is those subjects who receive at least one dose of trial drug and who have follow-up safety data.
Description of Statistical Analyses
General Considerations
All statistical tests will be performed at the 0.05 significance level. 95% confidence intervals will be calculated whenever appropriate.
Only available data will be considered for analysis. Subjects who discontinue the study prematurely will be considered as missing data and will be dropped from the statistical analysis.
9.
Ethical and Regulatory Aspects
Responsibilities of the Investigator
The Investigator is responsible for the conduct of the trial at his/her site. He/she will ensure that the trial is performed in accordance with the Declaration of Helsinki, as well as with the ICH Note for Guidance on Good Clinical Practice (ICH E6, 1996) and applicable regulatory requirements. In particular, the Investigator must ensure that only subjects who have given their informed consent are included into the trial.
Subject Information and Informed Consent
Implementation of the above item should comply with the ICH-GCP guidelines (ICH，E6， 1996), management regulations of the clinical trial and applicable regulations of local hospital. 
Subjects Insurance
Compensation for the subject should comply with state laws, the GCP rule, terms of the insurance company and relevant regulations of the hospitals participating in the study.
Ethics Committee or Institutional Review Board
Prior to commencement of the trial, the trial protocol will be submitted together with its associated documents (subject information, consent form, investigator handbook) to the responsible Independent Ethics Committee (IEC)/Institutional Review Board (IRB) for its favorable opinion/approval. The written favorable opinion/approval of the IEC/IRB must be obtained before initiation of the trial.
Trial Management
Case Report Form Handling
The main purpose of the Case Report Form (CRF) is to obtain those data required by the trial protocol in a complete, accurate, legible and timely fashion. The data in the CRF should be consistent with the relevant source documents.
Detailed procedure should comply with the ICH-GCP guidelines, management regulations of the clinical trial and applicable regulations of local hospital.
Source Data and Subject Files
The Investigator must keep a subject file (medical file, original medical records) on paper or electronically for every subject included in the trial. This file will contain the available demographic and medical information for the subject, and should be as complete as possible.
In particular, the following data should be available in this file: 
Investigator Site File and Archiving
Monitoring, Quality Assurance and Inspection by Authorities
Detailed procedure should comply with the ICH-GCP guidelines, management regulations of the clinical trial, sponsor and applicable regulations of local hospital.
Changes to the Protocol
Clinical Trial Report and Publication Policy
Clinical Trial Report
After conclusion of the trial, a clinical trial report will be written by the Sponsor in 25 consultation with the Coordinating Investigator and other relevant committees or groups.
The first author of the publication shall be the Coordinating Investigator or other investigators designated by the Coordinating Investigator.
Publication
The first publication will be a publication of the results of the analysis of the primary endpoint(s) that will include data from all trial sites.
The Investigator will inform the Sponsor in advance about any plans to publish or present data from the trial. Any publications and presentations of the results (abstracts in journals or newspapers, oral presentations, etc.), either in whole or in part, by Investigators or their representatives will require pre-submission review and written approval of the Sponsor.
The Sponsor will not suppress or veto publications, but maintains the right to delay publication for 3 months in order to protect intellectual property rights.
